Top-line results from the Phase Ib study with YELIVA™ (ABC294640) in patients with advanced solid tumors are expected to be announced in the coming weeks
Nomura's specialty pharmaceuticals and generics industry analyst, initiated coverage of the sector with five Buy-rated recommendations.
eines davon ist halt RDHL
RedHill Biopharma Ltd – ADR (NASDAQ: RDHL) currently has three phase III candidates with a total market opportunity of $10.3 billion. Accordingly, the stock represents an "attractive" long-term investment.